Pfizer (PFE) just laid out a 2026 outlook that underwhelmed the market, with lower expected earnings and revenue as COVID-19 ...
If you are wondering whether Pfizer at around $25 a share is a value trap or a genuine opportunity, this breakdown will help you decide whether it deserves a spot on your watchlist right now. Despite ...
In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House ...
Pfizer Inc. (NYSE:PFE), one of the world's largest pharmaceutical companies with a market capitalization of $151.25 billion, finds itself at a critical juncture as it navigates the post-pandemic ...
MarketBeat on MSN
Pfizer: Can $108B Bet on Obesity Drugs Revive Its Struggling Stock?
Grand View Research found that North America accounts for the largest revenue share, with more than 75% of the GLP-1 agonists market. While other alternative obesity interventions exist, including ...
Pfizer says data supports its request for Food and Drug Administration approval of a third dose of the COVID-19 vaccine about six months after the... The Food and Drug Administration released an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback